Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226119 · ClinicalTrials.gov registry record · Phase 4
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
A Phase 4 study of HTLV-I Infections and HTLV-II Infections, sponsored by MP Biomedicals.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT03226119: Completed Phase 4 study of HTLV-I Infections and HTLV-II Infections, sponsored by MP Biomedicals.
NCT03226119 is a Phase 4 study of HTLV-I Infections and HTLV-II Infections that has completed, run by MP Biomedicals. The registered enrollment target is 150 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03226119, a Phase 4 study of HTLV-I Infections and HTLV-II Infections, has completed, sponsored by MP Biomedicals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MP Diagnostics HTLV Blot 2.4
Study Locations (3)
Pennsylvania
- LABS, Inc. - Philadelphia
Texas
- Qualtex Laboratories - San Antonio
Virginia
- Eastern Virginia Medical School (EVMS) - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 4 |
What the finished NCT03226119 record still lists
NCT03226119 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 6 conditions, with HTLV-I Infections appearing as the primary indexed condition, and to 1 intervention - of which MP Diagnostics HTLV Blot 2.4 is the first listed.
NCT03226119 reports a single indexed study location in Pennsylvania, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT03226119 about?
NCT03226119 is a clinical study titled "MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study". This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
What is the current status of trial NCT03226119?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2018-01-15. Estimated completion is 2018-08-31.
What conditions does trial NCT03226119 study?
This clinical trial studies the following conditions: HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma.
What interventions are being tested in trial NCT03226119?
The interventions under investigation include: MP Diagnostics HTLV Blot 2.4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03226119?
This trial is sponsored by MP Biomedicals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226119 being conducted?
This trial has 3 study locations across Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03226119's enrollment target sits among peer trials
150 533rd of 2000 higher than 1,436 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI